485 related articles for article (PubMed ID: 27233604)
1. Molecular dynamics simulation and free energy landscape methods in probing L215H, L217R and L225M βI-tubulin mutations causing paclitaxel resistance in cancer cells.
Tripathi S; Srivastava G; Sharma A
Biochem Biophys Res Commun; 2016 Aug; 476(4):273-279. PubMed ID: 27233604
[TBL] [Abstract][Full Text] [Related]
2. Structural investigations into the binding mode of novel neolignans Cmp10 and Cmp19 microtubule stabilizers by in silico molecular docking, molecular dynamics, and binding free energy calculations.
Tripathi S; Kumar A; Kumar BS; Negi AS; Sharma A
J Biomol Struct Dyn; 2016 Jun; 34(6):1232-40. PubMed ID: 26212016
[TBL] [Abstract][Full Text] [Related]
3. Mutations at leucine 215 of beta-tubulin affect paclitaxel sensitivity by two distinct mechanisms.
Wang Y; Yin S; Blade K; Cooper G; Menick DR; Cabral F
Biochemistry; 2006 Jan; 45(1):185-94. PubMed ID: 16388594
[TBL] [Abstract][Full Text] [Related]
4. A beta-tubulin leucine cluster involved in microtubule assembly and paclitaxel resistance.
Gonzalez-Garay ML; Chang L; Blade K; Menick DR; Cabral F
J Biol Chem; 1999 Aug; 274(34):23875-82. PubMed ID: 10446152
[TBL] [Abstract][Full Text] [Related]
5. Investigation of Paclitaxel Resistant R306C Mutation in β-Tubulin—A Computational Approach.
Verma K; Ramanathan K
J Cell Biochem; 2015 Jul; 116(7):1318-24. PubMed ID: 25735511
[TBL] [Abstract][Full Text] [Related]
6. Binding modes of cabazitaxel with the different human β-tubulin isotypes: DFT and MD studies.
Zhu L; Zhang C; Lü X; Song C; Wang C; Zhang M; Xie Y; Schaefer HF
J Mol Model; 2020 May; 26(6):162. PubMed ID: 32474655
[TBL] [Abstract][Full Text] [Related]
7. βI-tubulin mutations in the laulimalide/peloruside binding site mediate drug sensitivity by altering drug-tubulin interactions and microtubule stability.
Kanakkanthara A; Rowe MR; Field JJ; Northcote PT; Teesdale-Spittle PH; Miller JH
Cancer Lett; 2015 Sep; 365(2):251-60. PubMed ID: 26052091
[TBL] [Abstract][Full Text] [Related]
8. Dietary flavonoid fisetin binds to β-tubulin and disrupts microtubule dynamics in prostate cancer cells.
Mukhtar E; Adhami VM; Sechi M; Mukhtar H
Cancer Lett; 2015 Oct; 367(2):173-83. PubMed ID: 26235140
[TBL] [Abstract][Full Text] [Related]
9. Elucidating the mechanism of action of the clinically approved taxanes: a comprehensive comparison of local and allosteric effects.
Churchill CD; Klobukowski M; Tuszynski JA
Chem Biol Drug Des; 2015 Nov; 86(5):1253-66. PubMed ID: 26032329
[TBL] [Abstract][Full Text] [Related]
10. DTA0100, dual topoisomerase II and microtubule inhibitor, evades paclitaxel resistance in P-glycoprotein overexpressing cancer cells.
Podolski-Renić A; Banković J; Dinić J; Ríos-Luci C; Fernandes MX; Ortega N; Kovačević-Grujičić N; Martín VS; Padrón JM; Pešić M
Eur J Pharm Sci; 2017 Jul; 105():159-168. PubMed ID: 28502672
[TBL] [Abstract][Full Text] [Related]
11. Novel mutations involving βI-, βIIA-, or βIVB-tubulin isotypes with functional resemblance to βIII-tubulin in breast cancer.
Wang W; Zhang H; Wang X; Patterson J; Winter P; Graham K; Ghosh S; Lee JC; Katsetos CD; Mackey JR; Tuszynski JA; Wong GK; Ludueña RF
Protoplasma; 2017 May; 254(3):1163-1173. PubMed ID: 27943021
[TBL] [Abstract][Full Text] [Related]
12. Amino acid substitutions at proline 220 of beta-tubulin confer resistance to paclitaxel and colcemid.
Yin S; Cabral F; Veeraraghavan S
Mol Cancer Ther; 2007 Oct; 6(10):2798-806. PubMed ID: 17938271
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the effect of the chiral centers of Taxol on binding to β-tubulin: A docking and molecular dynamics simulation study.
Ghadari R; Alavi FS; Zahedi M
Comput Biol Chem; 2015 Jun; 56():33-40. PubMed ID: 25854803
[TBL] [Abstract][Full Text] [Related]
14. BetaIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability.
Kamath K; Wilson L; Cabral F; Jordan MA
J Biol Chem; 2005 Apr; 280(13):12902-7. PubMed ID: 15695826
[TBL] [Abstract][Full Text] [Related]
15. The Unique Binding Mode of Laulimalide to Two Tubulin Protofilaments.
Churchill CD; Klobukowski M; Tuszynski JA
Chem Biol Drug Des; 2015 Aug; 86(2):190-9. PubMed ID: 25376845
[TBL] [Abstract][Full Text] [Related]
16. Microtubules and resistance to tubulin-binding agents.
Kavallaris M
Nat Rev Cancer; 2010 Mar; 10(3):194-204. PubMed ID: 20147901
[TBL] [Abstract][Full Text] [Related]
17. Interaction of microtubule depolymerizing agent indanocine with different human αβ tubulin isotypes.
Kumbhar BV; Panda D; Kunwar A
PLoS One; 2018; 13(3):e0194934. PubMed ID: 29584771
[TBL] [Abstract][Full Text] [Related]
18. CKT0353, a novel microtubule targeting agent, overcomes paclitaxel induced resistance in cancer cells.
Dinić J; Ríos-Luci C; Karpaviciene I; Cikotiene I; Fernandes MX; Pešić M; Padrón JM
Invest New Drugs; 2020 Jun; 38(3):584-598. PubMed ID: 31177401
[TBL] [Abstract][Full Text] [Related]
19. Delineating the interaction of combretastatin A-4 with αβ tubulin isotypes present in drug resistant human lung carcinoma using a molecular modeling approach.
Kumbhar BV; Bhandare VV; Panda D; Kunwar A
J Biomol Struct Dyn; 2020 Feb; 38(2):426-438. PubMed ID: 30831055
[TBL] [Abstract][Full Text] [Related]
20. Cancer cells acquire mitotic drug resistance properties through beta I-tubulin mutations and alterations in the expression of beta-tubulin isotypes.
Cheung CH; Wu SY; Lee TR; Chang CY; Wu JS; Hsieh HP; Chang JY
PLoS One; 2010 Sep; 5(9):e12564. PubMed ID: 20838440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
